Page 7 - Arnold Lippa News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arnold lippa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arnold Lippa Today - Breaking & Trending Today

RespireRx Pharmaceuticals notes publication of paper on newest GABAkine analog which protects against seizures and lethality

RespireRx Pharmaceuticals (OTCQB:RSPI) Inc has noted the publication of a paper detailing the company s newest candidate D5-KRM-II-81, which is a so-called. ....

Jeffreym Witkin , Arnold Lippa , Respirerx Pharmaceuticals , Drug Disposition ,

RespireRx Pharmaceuticals Inc. Announces Publication of

Glen Rock, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery. ....

United States , Jamesm Cook , Michaelm Poe , Xiaoming Jin , Jeffreym Witkin , Lalitk Golani , Rok Cerne , Jeff Margolis , Jodil Smith , Arnold Lippa , Respirerx Senior Research Scientist , Company Contact , Company Endeavourrx , Respirerx Pharmaceuticals Inc , American Academy Of Sleep Medicine , Exchange Commission , Company Annual Report On Form , University Of Wisconsin , Milwaukee Research Foundation Inc , Indiana University Purdue , Securities Exchange , Respirerx Research Fellows , Glen Rock , Purdue University , Respirerx Executive Chairman , Chief Scientific Officer ,

RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs
RespireRX Pharmaceuticals Inc.April 22, 2021 GMT
Glen Rock, N.J., April 22, 2021 (GLOBE NEWSWIRE) RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to provide an update on its therapeutic drug development programs.
EndeavourRx
Scientists associated with the Company have been invited by the prestigious journal,
Pharmacology and Therapeutics, to publish a review article describing the preclinical properties of its lead GABAkine compound, KRM-II-81, and its potential clinical therapeutic applications. The multidisciplinary team of authors have been led by Dr. James M. Cook6,7, Distinguished Professo ....

United States , Slovenia General , Jamesm Cook , Tim Jones , Michael Poe , Jeffrey Witkin , Respirerx Endeavourrx , Xiaoming Jin , Jeffreym Witkin , Lalitk Golani , Jeff Margolis , Arnold Lippa , Jodil Smith , Company Contact , University Of Florida , Respirerx Pharmaceuticals Inc , Senior Research Scientist , American Academy Of Sleep Medicine , Indiana University Purdue , Respirerx Research Fellows , Milwaukee Institute Of Drug Discovery , Department Of Anatomy , Department Of Chemistry , University Of Wisconsin , Exchange Commission , Milwaukee Research Foundation Inc ,